Product Center
IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-30
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly submitted an Investigational New Drug (IND) application for a Class I new drug—the "Influenza Virus Subunit Vaccine (Adjuvanted)"—which has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This approval marks the completion of the company’s full pipeline coverage for subunit influenza vaccines, including both trivalent and quadrivalent formulations, offering tailored options for diverse age groups and populations with specific needs.
IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly submitted an Investigational New Drug (IND) application for a Class I new drug—the "Influenza Virus Subunit Vaccine (Adjuvanted)"—which has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This approval marks the completion of the company’s full pipeline coverage for subunit influenza vaccines, including both trivalent and quadrivalent formulations, offering tailored options for diverse age groups and populations with specific needs.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-30 14:49
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly submitted an Investigational New Drug (IND) application for a Class I new drug—the "Influenza Virus Subunit Vaccine (Adjuvanted)"—which has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This approval marks the completion of the company’s full pipeline coverage for subunit influenza vaccines, including both trivalent and quadrivalent formulations, offering tailored options for diverse age groups and populations with specific needs.
Source: Official Website of the Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA)
Currently, the influenza virus remains one of the most significant respiratory pathogens threatening global public health. Seasonal outbreaks or sporadic cross-species transmission and pandemics significantly impact human health and socioeconomic development. Compared to other age groups, the elderly face higher infection rates and greater risks of severe illness or death from influenza, with risks escalating with age. Both the World Health Organization (WHO) and the Chinese Center for Disease Control and Prevention (China CDC) recommend the elderly as a priority group for influenza vaccination.
The newly approved trivalent influenza virus subunit vaccine (adjuvanted), developed by Ab&B Bio, aligns with WHO recommendations and leverages the company’s proven platform technology and novel adjuvant formulations. It is specifically designed for individuals aged 65 and older. Preclinical studies demonstrate that this adjuvanted vaccine significantly elevates antibody levels and neutralizing antibody titers, offering superior immune response enhancement—making it the optimal choice for elderly populations vulnerable to influenza.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
